These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29216560)

  • 21. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
    Tirmenstein M; Dorr TE; Janovitz EB; Hagan D; Abell LM; Onorato JM; Whaley JM; Graziano MJ; Reilly TP
    Int J Toxicol; 2013; 32(5):336-50. PubMed ID: 24097127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
    Komoroski B; Vachharajani N; Feng Y; Li L; Kornhauser D; Pfister M
    Clin Pharmacol Ther; 2009 May; 85(5):513-9. PubMed ID: 19129749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
    Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.
    Chu KF; Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Chang WE; Chao YS; Lee JC
    Bioorg Med Chem; 2016 May; 24(10):2242-50. PubMed ID: 27075813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes.
    Kong YK; Song KS; Jung ME; Kang M; Kim HJ; Kim MJ
    Bioorg Med Chem Lett; 2022 Jan; 56():128466. PubMed ID: 34813882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes.
    Sayed N; Abdalla O; Kilany O; Dessouki A; Yoshida T; Sasaki K; Shimoda M
    J Vet Med Sci; 2020 Apr; 82(4):467-474. PubMed ID: 32161237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Kim GW; Chung SH
    Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
    Trujillo JM; Nuffer WA
    Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
    Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
    PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
    Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
    J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
    Pan X; Huan Y; Shen Z; Liu Z
    Eur J Med Chem; 2016 May; 114():89-100. PubMed ID: 26974378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Contributions of SGLT-2 and new drugs under investigation].
    Mediavilla Bravo JJ
    Semergen; 2014 Jul; 40 Suppl 2():34-40. PubMed ID: 25311718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners.
    Kim MJ; Lee J; Kang SY; Lee SH; Son EJ; Jung ME; Lee SH; Song KS; Lee M; Han HK; Kim J; Lee J
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3420-5. PubMed ID: 20434909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
    Li Y; Shi Z; Chen L; Zheng S; Li S; Xu B; Liu Z; Liu J; Deng C; Ye F
    J Med Chem; 2017 May; 60(10):4173-4184. PubMed ID: 28447791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
    Vivian E
    Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel SGLT2 inhibitor, SU-011, improves glycaemic control in rodents without the risk of hypoglycaemia and weight gain.
    Huang F; Dai F; Bi J; Hao L; Wang C; Xu K; Liu Y; Cheng X
    J Pharm Pharmacol; 2019 Sep; 71(9):1393-1399. PubMed ID: 31218683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
    Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
    J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Lee SH; Song KS; Kim JY; Kang M; Lee JS; Cho SH; Park HJ; Kim J; Lee J
    Bioorg Med Chem; 2011 Oct; 19(19):5813-32. PubMed ID: 21906953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
    Kumar S; Khatik GL; Mittal A
    Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.